A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Inclusion Criteria:

- Metastatic disease or locally advanced, unresectable disease.

- Has histopathologically confirmed gastric or GEJ adenocarcinoma with documented
disease progression after 0-2 prior lines of systemic therapy

- Has histopathologically confirmed nonsquamous or squamous NSCLC with documented
disease progression after 0-3 prior lines of systemic therapy

- Has histopathologically confirmed transitional cell carcinoma of the urothelium
(bladder, urethra, or renal pelvis) with documented disease progression after 1-3
prior lines of systemic therapy

- Has histologically confirmed biliary tract adenocarcinoma with documented
progression after 1-2 prior lines of systemic therapy

- Availability of tumor tissue for biomarker analysis from a newly obtained core or
excisional biopsy or willing to undergo a tumor biopsy. For first line NSCLC
participants only, PD-L1 expression should be 1% or higher.

- Have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.

- Has adequate organ function.

- Have an anticipated life expectancy of ≥3 months.

Exclusion Criteria:

- Have known brain metastases.

- Has received ≥3 lines of prior systemic therapy for gastric or GEJ adenocarcinoma and
BTC or ≥4 lines for NSCLC or urothelial cancer.

- Has active autoimmune disease.

- Known human immunodeficiency virus (HIV) infection.

- Known active hepatitis B or hepatitis C infection.

- Has received any previous systemic therapy targeting vascular endothelial growth
factor (VEGF) or VEGF receptor, or programmed death (PD) 1 or PD-ligand 1/2 signaling
pathways.

- Have received a live vaccine within 30 days prior to enrollment. Seasonal flu vaccines
that do not contain live virus are permitted.

- Have had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior
to enrollment.

- Have an elective or a planned major surgery during the course of the trial or has
undergone major surgery within 28 days prior to enrollment.